Evidence map›Paper›PMID 42224394›Full record

ArticlePloS one2026

Which evolutionary game-theoretic model best captures NSCLC dynamics?

Hasti Garjani, Johan Dubbeldam, Kateřina Staňková, Joel S Brown

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hasti GarjaniDelft Institute of Applied Mathematics, Delft University of Technology, Delft, The Netherlands.ORCID https://orcid.org/0000-0002-8587-1870
Johan DubbeldamDelft Institute of Applied Mathematics, Delft University of Technology, Delft, The Netherlands.
Kateřina StaňkováInstitute for Health Systems Science, Delft University of Technology, Delft, The Netherlands.ORCID https://orcid.org/0000-0002-4519-0325
Joel S BrownIntegrated Mathematical Oncology, H. Lee Moffitt Cancer and Research Institute, Tampa, Florida, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Understanding and predicting the eco-evolutionary dynamics of cancer requires identifying mathematical models that best capture tumor growth and treatment response. In this study, we fit a family of two-population models to in-vitro data from non-small cell lung cancer (NSCLC), tracking drug-sensitive and drug-resistant cells under varying environmental conditions. The dataset, originally presented by Kaznatcheev et al., includes conditions with and without the drug Alectinib and cancer-associated fibroblasts (CAFs). We compare combinations of growth models (logistic, Gompertz, and von Bertalanffy) and drug efficacy terms (Norton-Simon, linear, and ratio-dependent) to identify which best explains the observed dynamics. Our models incorporate density dependence, frequency-dependent competition, and drug response, enabling mechanistic interpretation of tumor cell interactions. The logistic model with ratio-dependent drug efficacy best fits monoculture data. Using growth parameters from monocultures, we estimate inter-type competition coefficients in co-cultures. We find that growth rate and carrying capacity are stable across CAF conditions, while competition and drug efficacy parameters shift, altering interaction dynamics. Notably, CAFs promote coexistence between resistant and sensitive cells, whereas Alectinib results in competitive exclusion. Our results underscore the need to evaluate both model fit and biological plausibility to guide therapeutic modeling of cancer.

Indexed as

Carcinoma, Non-Small-Cell LungGame TheoryLung NeoplasmsModels, BiologicalCarbazolesCell Line, TumorCell ProliferationDrug Resistance, NeoplasmFibroblastsHumansPiperidinesalectinibCarbazolesPiperidines

Identifiers

PMID42224394
PMCPMC13225666

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.